Business Wire

Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments

Share

Incyte (Nasdaq:INCY) today announced efficacy and safety results from a pooled analysis of two randomized, double-blind, vehicle-controlled Phase 3 studies – TRuE-AD1 and TRuE-AD2 – evaluating ruxolitinib cream for the treatment of patients with mild-to-moderate atopic dermatitis (AD). The presentation (FC08.08) will be available on-demand as part of the 29th European Academy of Dermatology and Venereology (EADV) Congress, held virtually from October 29-31, 2020.

Key findings from the individual TRuE-AD1 and TRuE-AD2 studies were previously reported.

The new, pooled data reinforce that treatment with ruxolitinib cream resulted in a rapid, substantial and sustained reduction in itch; and improved the extent and severity of AD as measured by the Eczema Area Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD) assessment tools.

In addition, treatment with ruxolitinib cream resulted in notable improvements in quality of life measures such as the PROMIS (Patient-Reported Outcomes Measurement Information System)1 sleep disturbance (8b)2 score. PROMIS is a set of well-accepted patient-reported outcome measurement tools that are psychometrically supported.1 In the TRuE-AD trials, the PROMIS Short Form-Sleep Disturbance (8b) questionnaire was used to assess patients’ self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep.

Key results from the pooled analysis include:

Ruxolitinib cream 0.75% BID

Ruxolitinib cream 1.5% BID

Vehicle

Primary endpoint

IGA-TS, responders

n=483

n=481

n=244

44.7%*

52.6%*

11.5%

Key secondary endpoints

EASI-75, responders

n=483

n=481

n=244

53.8%*

62.0%*

19.7%

Itch NRS (≥4-point improvement), responders

n=313

n=307

n=158

41.5%*

51.5%*

15.8%

PROMIS Short Form-Sleep Disturbance (8b) (≥6-point improvement), responders

n=446

n=449

n=226

20.9%**

23.8%**

14.2%

Secondary endpoint

SCORAD, mean change from baseline

n=483

n=481

n=244

-62.9%*

-67.3%*

-30.4%

Additional efficacy analysis

Daily Itch NRS Score, mean change from baseline within 12 hours

n=483

n=481

n=244

-0.4***

-0.5***

-0.1

IGA-TS: Investigator’s Global Assessment (IGA)-Treatment Success defined as an IGA score of 0 (clear) or 1 (almost clear) with ≥2-point improvement from baseline at Week8; BID: twice daily; EASI-75: ≥75% improvement from baseline at Week 8 in the Eczema Area and Severity Index (EASI) score; NRS: Numerical Rating Scale; PROMIS: Patient-Reported Outcomes Measurement Information System; SCORAD: Scoring Atopic Dermatitis.
Patients included in the analysis had an Itch NRS score ≥4 at baseline; Patients included in the analysis had a PROMIS Short Form-Sleep Disturbance (8b) score of ≥6 at baseline.
*P<0.0001 vs. vehicle at Week 8; **P<0.05 vs. vehicle at Week 8; ***P<0.02 vs. vehicle.

The overall safety profile of ruxolitinib cream was consistent with previously reported data, with no new safety signals observed in this pooled analysis.

“Atopic dermatitis is a chronic inflammatory skin condition that may result in decreased quality of life for patients; attributable in part to sleep disturbances resulting from intense and persistent itch,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. “Pooled results from the TRuE-AD studies reinforce the potential of ruxolitinib cream to become an important antipruritic and anti-inflammatory treatment option for patients with atopic dermatitis and we are on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration at the end of this year.”

About Atopic Dermatitis

Atopic dermatitis (AD) is a common chronic and intensely pruritic disease characterized by inflammation of the skin. AD affects more than 30 million individuals in the United States and 80-90% of patients have mild-to-moderate disease. Signs and symptoms of AD include irritated and itchy skin that can cause red lesions that may ooze and crust. Patients with AD are also more susceptible to bacterial, viral and fungal infections.

About TRuE-AD

The TRuE-AD clinical trial program consists of two randomized, double-blind, vehicle-controlled Phase 3 studies, TRuE-AD1 (NCT03745638) and TRuE-AD2 (NCT03745651), evaluating the safety and efficacy of ruxolitinib cream compared to vehicle (non-medicated cream) in patients with atopic dermatitis (AD). Both studies enrolled more than 600 patients (age ≥12 years) diagnosed with AD for at least two years and who were candidates for topical therapy.

Patients with an Investigator’s Global Assessment (IGA) score of 2 to 3, and with AD on 3% to 20% of their Body Surface Area (excluding scalp) were randomized 2:2:1 into one of three arms for eight weeks: ruxolitinib cream 0.75% applied twice daily (BID); ruxolitinib cream 1.5% applied BID; and vehicle. Participants who successfully completed an assessment at Week 8 were offered participation in the 44-week long-term safety treatment extension period with ruxolitinib cream 0.75% or 1.5% applied BID.

The primary endpoint of the TRuE-AD studies was the proportion of participants achieving an Investigator’s Global Assessment Treatment Success (IGA-TS), defined as an IGA score of 0 (clear) or 1 (almost clear) with at least a 2-point improvement from baseline at Week 8. Key secondary endpoints include: the proportion of patients achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index (EASI-75) score, the proportion of participants with at least a 4-point improvement in the itch Numerical Rating Scale, and the proportion of participants with at least a 6-point improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form – Sleep Disturbance (8b) 24-hour recall score. Additional secondary endpoints include mean percentage change from baseline in Scoring Atopic Dermatitis (SCORAD) score. The studies have also been tracking the frequency, duration and severity of adverse events associated with the use of ruxolitinib cream.

For more information about the TRuE-AD studies, please visit http://clinicaltrials.gov/ct2/show/NCT03745638 and http://clinicaltrials.gov/ct2/show/NCT03745651.

About Ruxolitinib Cream

Ruxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of patients with mild-to-moderate atopic dermatitis (TRuE-AD) and for the treatment of adolescents and adults with vitiligo (TRuE-V). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.

About Incyte Dermatology

Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company’s research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.

Currently, Incyte is exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa. To learn more, visit the Dermatology section of Incyte.com.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements about the potential of ruxolitinib cream to provide a meaningful treatment for patients with atopic dermatitis, the TRuE-AD clinical program, the Company’s Dermatology program, the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis, and expected timing of the filing of the NDA for ruxolitinib cream for the treatment of atopic dermatitis, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the efficacy or safety of the Company’s products; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.

PROMIS® is a registered trademark of the U.S. Department of Health and Human Services.

References:

  1. PROMIS. HealthMeasures. Available at: https://www.healthmeasures.net/explore-measurement-systems/promis. Accessed on October 28, 2020.
  2. Buysse DJ, et. al. Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep 2010; 33:781-792.

Contact information

Media

Catalina Loveman, +1 302 498 6171
cloveman@incyte.com

Nupur Patel, PharmD, +1 302 498 5822
npatel@incyte.com

Investors

Michael Booth, DPhil, +1 302 498 5914
mbooth@incyte.com

Christine Chiou, +1 302 274 4773
cchiou@incyte.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global Electronic Toll Collection and Road Usage Charging market to reach €490 billion in 20302.12.2020 17:06:00 CETPress release

As the UK government just announced it is considering Road Usage Charging (RUC) as a funding solution for its road network, RUC schemes are being pushed ahead around the world. In the US, Asia, Africa and Oceania, electronic tolling is becoming crucial to bridge financing gaps and substitute declining gas tax receipts. PTOLEMUS Consulting Group forecasts that 874 million global subscriptions in ETC/RUC schemes will be active by 2030, collecting over €490 billion every year by 2030. PTOLEMUS’ Electronic Tolling Global Study is the 3rd edition of its highly popular Electronic Tolling series of reports, and represents the most comprehensive review of the global ETC/RUC market to-date, including 950 pages of insights, data, analyses and forecasts. PTOLEMUS expects the global ETC/RUC market to grow at 13% CAGR to 2030, driven by multiple factors including: environmental policy, economic development, interoperability schemes and growth of cashless payments, propelled by COVID-19. Dr Andrew J

Continental Structural Plastics Perfects Carbon Fiber RTM Process, Launches Production Programs2.12.2020 16:27:00 CETPress release

After winning a JEC Innovation Award in 2016 for its Lincoln MKS Decklid Concept – a TCA Ultra Lite® outer panel and a carbon fiber RTM prototype inner – Continental Structural Plastics (CSP) has fine-tuned its carbon fiber RTM (CF-RTM) process to the point that a premium automaker will be using the technology for closures on future vehicle platforms. These doors will feature both inner and outer panels as well as structural reinforcements molded using CSP’s advanced CF-RTM process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201202005708/en/ The new carbon fiber RTM press installed at the CSP facility in Palmela, Portugal, will soon be running the company's first commercial applications of this technology. (Photo: Business Wire) When CSP set up its Center of Excellence for Lightweight Technologies and Carbon Fiber Processes in Pouancé, France, in 2013, the goal was to develop processes to make the use of carbon fiber in

Pricefx Reimagines Pricing Software with Groundbreaking Product Enhancements2.12.2020 15:30:00 CETPress release

Pricefx, the global leader in cloud-native pricing software, today announced the new face of its pricing platform. Unity UI is a sleek, dynamic new look for all of Pricefx’s industry-leading pricing modules. The company has also launched PriceOptimizer AI, a next-generation price optimization solution powered by transparent and predictive machine learning and multi-agent AI. Finally, Pricefx introduced new Accelerators, pre-defined solution building blocks that quickly and easily incorporate best practice functionality. With these new enhancements, Pricefx is now more streamlined, powerful and agile than ever before. Now, businesses using Pricefx can get more done and price more effectively with fewer clicks. “2020 revealed the critical importance of pricing in a digital-first world and Pricefx invested heavily in developing and refining our pricing platform to ensure that businesses around the world can successfully use our software to build a path to growth,” said Marcin Cichon, CEO

Soar the Skies with Demon Avenger in New MapleStory M Update2.12.2020 15:00:00 CETPress release

Starting today, Maplers can take to the sky with the new warrior class, Demon Avenger, in Nexon’s free-to-play mobile MMORPG, MapleStory M! This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201202005043/en/ MapleStory M (Graphic: Business Wire) Soaring through the battlefield with Demon Wings, the Demon Avenger joins the fray with an Exceed System that deals excessive damage. Using HP to cast skills, the Demon Avenger can easily recover using various healing abilities, including Blood Pact, in the midst of battle. A selection of limited-time events are also available, including: Demon Avenger Celebratory Log-in Reward Event: Players logging in from today through December 7, 2020 will receive a special gift to help their character level up once per account. Demon Avenger Growth Support Event: Until January 11, 2021, players who reach a certain level will receive additional in-game items useful for a specific character’s level-up

Uber, Rivian, JetBlue, Cabify, and Boom Supersonic Sign The Climate Pledge2.12.2020 15:00:00 CETPress release

Today, during Web Summit 2020, Amazon (NASDAQ: AMZN) and Global Optimism announced that Boom Supersonic, Cabify, JetBlue, Rivian, and Uberhave joined The Climate Pledge, a commitment to be net-zero carbon by 2040—a decade ahead of the Paris Agreement’s goal of 2050. Signatories to The Climate Pledge agree to: Measure and report greenhouse gas emissions on a regular basis; Implement decarbonization strategies in line with the Paris Agreement through real business changes and innovations, including efficiency improvements, renewable energy, materials reductions, and other carbon-emission elimination strategies; Neutralize any remaining emissions with additional, quantifiable, real, permanent, and socially beneficial offsets to achieve net-zero annual carbon emissions by 2040. “By signing The Climate Pledge, companies around the world are making a bold commitment to help protect our planet from the devastating impacts of climate change,” said Jeff Bezos, Amazon founder and CEO. “The trans

DXC Technology and Microsoft Collaborate to Power a More Personalized, Intelligent, Secure and Modern Workplace Experience for Global Enterprises2.12.2020 14:30:00 CETPress release

DXC Technology (NYSE: DXC) today announced an expanded strategic collaboration with Microsoft to deliver a more personalized, intelligent, secure and modern workplace experience to help companies to address rapidly evolving business challenges and customer and employee needs. DXC and Microsoft are joining forces to deliver a solution and suite of services that will help companies to empower their employees with a modern workplace experience and to ensure customers’ employees can seamlessly and securely work anytime, anywhere and on any device. Called DXC MyWorkStyle™, DXC brings the largest install base of workplace customers and the blueprint for the modern workplace experience. As part of the collaboration, Microsoft and DXC will work together to co-develop and deliver the solution, leveraging artificial intelligence and machine learning from millions of data points to create a modern workplace experience. DXC and Microsoft will bring together leading technology, engineering talent a